Melanoma/Skin Cancer News

Mohs micrographic surgery was superior to wide local excision as measured by local recurrence rates in a cohort of patients with T2a squamous cell carcinoma, according to a study.

Continuous dosing of dabrafenib and trametinib conferred superior PFS compared with intermittent dosing of the targeted agents among patients with BRAF V600E- and V600K-mutant melanoma, according to results of a randomized phase 2 study presented at the virtual American Association for Cancer Research Annual Meeting.

The addition of atezolizumab to cobimetinib and vemurafenib significantly prolonged PFS and conferred durable responses among patients with BRAF V600 mutation-positive advanced melanoma, according to results of the randomized phase 3 IMspire150 study presented at the virtual American Association for Cancer Research Annual Meeting.

A 56-year-old woman with no significant past medical history presented with 6-month history of a painless right heel cutaneous lesion. On exam, she had a non-tender melanotic lesion measuring approximately 2 cm x 2 cm with irregular borders and central ulceration involving the right medial heel pad (Figure 1). There was no palpable lymphadenopathy and the right lower extremity was neurovascularly intact.

Patients with facial skin cancers appeared to have unrealistic expectations regarding scarring after Mohs micrographic surgery, according to results of prospective, cross-sectional study published in JAMA Network Open.

Melanoma incidence rates differ between men and women by age and anatomic site in predominantly fair-skinned populations, according to a cross-sectional analysis published in JAMA Dermatology.

Three-quarters of patients would recommend artificial intelligence as a component of clinical decision-making for skin cancer, according to a survey.

The introduction and approval of new treatments for metastatic melanoma has led to significant declines in population-level mortality over the past several years, according to results of a retrospective study published in American Journal of Public Health.

A phase 3 trial designed to evaluate SGX301 for treatment of cutaneous T-cell lymphoma met its primary endpoint, according to the agent’s manufacturer.

About three-quarters of patients with advanced melanoma who achieved complete responses to single-agent anti-PD-1 therapy remained in remission at 3 years, according to results of a single-center retrospective study published in Journal of Clinical Oncology.